Gilead Sciences stock: anito-cel launch plan targets 200 centers
Published on 11/13/2026 at 16:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSLaunch preparation moves ahead
- Gilead plans to introduce anito-cel for patients with relapsed or refractory multiple myeloma after at least three prior treatment lines.
- The FDA action target is December 23, 2026, while the company is preparing manufacturing, center readiness and reimbursement processes.
- Updated anito-cel data are scheduled for the ASH annual meeting in December.
Gilead Sciences outlined a broader launch plan for its investigational CAR T-cell therapy anito-cel at the Wolfe Research Healthcare Conference on Tuesday, November 10. According to Investing.com, Gilead expects a potential launch in late 2026 or early 2027 if the therapy receives regulatory clearance.
The initial indication would cover patients with relapsed or refractory multiple myeloma who have received at least three prior lines of treatment. The company plans to build on Kite's existing cell-therapy infrastructure, with manufacturing for anito-cel operating in-house.
Operational scale becomes the focus
Gilead's Kite unit plans to work with 200 authorized treatment centers in the United States. Management said the rollout will require center contracts, electronic ordering integration, formulary decisions and payer reimbursement. The company expects 80% of the authorized centers to come on board within six months and 90% of payers to reimburse the therapy within the first year.
The regulatory timetable remains a key catalyst. Gilead's November 4 announcement said the anito-cel application was under FDA review with a Prescription Drug User Fee Act target action date of December 23, 2026. The target concerns FDA action, while the outcome of the review remains open.
Clinical evidence remains ahead
Gilead and Kite plan to present updated iMMagine-1 results at the American Society of Hematology annual meeting from December 12 to 15. The company said the presentation will include at least 18 months of follow-up on efficacy, safety, progression-free survival and overall survival in relapsed or refractory multiple myeloma.
Gilead Sciences stock was last quoted at 154.36 euros on Lang & Schwarz at 15:42 Berlin time on Thursday, November 12. The quote is separate from the company's regulatory and launch plans.
Gilead Sciences at a glance
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- WKN: 885823
- Security identifier: GIS
- Quoted price: 154.36 euros on Lang & Schwarz, November 12, 2026, 15:42 Berlin time
- Regulatory milestone: FDA action target on December 23, 2026
Investors are also watching broader developments in the US biotechnology market through current market reports.
More news and analyses on Gilead Sciences stock.
